What is Novo Nordisk doing to make Wegovy and Ozempic more affordable?

Novo Nordisk is reducing the cash price of Wegovy and Ozempic by 30% to $349 per month, down from $499, in order to improve affordability and accessibility of these medications for patients.

How will the price cut on Wegovy and Ozempic impact patients?

The price reduction will provide immediate cost savings for patients without insurance coverage or who choose to self-pay for these medications, making them more accessible to those who need them.

What is Novo Nordisk's strategy to expand access to Wegovy and Ozempic?

Novo Nordisk is building relationships with telehealth providers and major retailers, expanding coverage, and working with the administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes.

Home / Health / Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US

Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US

18 Nov, 2025

•

Summary

Novo Nordisk reduces cash price of Wegovy and Ozempic by 30% to $349 per month
Price cut aims to improve affordability and accessibility of these medications
Novo Nordisk expanding coverage and working to lower costs for patients

Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US

On November 18, 2025, the Danish pharmaceutical company Novo Nordisk announced a significant price reduction for its popular weight-loss drug Wegovy and diabetes medication Ozempic in the United States. Effective immediately, the new monthly cash price for either of these GLP-1 drugs will be $349, down from the previous $499.

Novo Nordisk's executive vice president, Dave Moore, stated that the company is committed to ensuring "real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them." The price cut is part of a broader strategy to expand access, including building relationships with telehealth providers, major retailers, and working with the administration to lower costs for patients living with chronic diseases like obesity and type 2 diabetes.